Literature DB >> 9687953

[Treatment of arterial femoropopliteal obstructions with Palmaz midsize stents].

S Müller-Hülsbeck1, H Schwarzenberg, J C Steffens, U Kopp, J Link, D Kutzner, C C Glüer, M Heller.   

Abstract

PURPOSE: To evaluate effectiveness, success and patency rates after endovascular treatment with mid-size Palmaz stents in high-grade stenoses or short-distance occlusions of femoral arteries.
MATERIALS AND METHODS: 27 patients with 10 occlusions (average length 3.2 +/- 1.4 cm) and 17 severe stenoses of the superficial femoral artery were treated with 33 mid-size Palmaz stents. The follow-up included Doppler ultrasound at one, three, 6 and 12 months and an angiography at 6 months. Mean follow-up was 6.5 months.
RESULTS: Technical success was 100%. The ankle-brachial index improved from 0.57 +/- 0.28 pretreatment to 0.87 +/- 0.13 within 24 hours. Acute stent thrombosis occurred in two patients (< 3 weeks). Angiography at 6 months revealed restenosis rates of 7.4% (> 50%, n = 2). Life-table analysis according to Kaplan-Meier revealed 6-month primary and secondary patency rates of 84% and 91%.
CONCLUSION: With regard to our limited data, the implantation of mid-size Palmaz stents in femoral arteries seems promising in treatment of short-distance occlusions and stenoses of the femoral artery.

Entities:  

Mesh:

Year:  1998        PMID: 9687953     DOI: 10.1055/s-2007-1015287

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  2 in total

1.  Implantation of the Corinthian IQ stent into the femoropopliteal arteries using 6-F introducer sheaths in antegrade and crossover procedures: midterm results.

Authors:  Roland Dorffner; Christian Neumann; Istvan Gergely; Reinhold Renner; Max Juhasz; Mathias Resinger; Georg Dorffner
Journal:  Eur Radiol       Date:  2003-04-23       Impact factor: 5.315

2.  Clopidogrel plus long-term aspirin after femoro-popliteal stenting. The CLAFS project: 1- and 2-year results.

Authors:  Ernst-Peter K Strecker; Irene B L Boos; Dieter Göttmann; Sylvia Vetter
Journal:  Eur Radiol       Date:  2003-07-10       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.